Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of GO321 Recombinant Oncolytic Virus Injection in Patients With Advanced Refractory Solid Tumors.

NCT07748117 is registered in ClinicalTrials.gov with GeneSail Biotech (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07748117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07748117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of GO321 Recombinant Oncolytic Virus Injection in Patients With Advanced Refractory Solid Tumors.
Lead sponsor
GeneSail Biotech (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 15, 2026
Completion date
December 31, 2028
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor malignancies